Lake Starnberg
Immunotherapy of Cancer
July 2-4, 2009
Program
Thursday July 2, 2009
4.30 PM Departure from Hotel Residence (by bus)
4.45 PM Arrival at La Villa - Aperitif
5.15–5.30 Opening remarks
K.-W. Jauch, Munich
5.30-6.15 Keynote lecture
Using chemokines to direct leukocyte traffic and impact on cancer therapy
F. Sallusto, Bellinzona, Switzerland
6.30 Dinner
Friday July 3, 2009
8:00-9:45 Session 1: Manipulating the (tumor) microenvironment to improve immunotherapeutic treatment strategies
Co-Chairs: Ch. Huber, Mainz – H. Winter, Munich
8:05-8:30 Manipulating regulatory T-cells to enhance anti-tumor
immunity
B.A. Fox, Portland, OR
8:30-8:55 DAMPs and redox: Role in inflammation and cancer
8:55-9:20 Biologic effects of vaccine adjuvants systemically and at the site of multipeptide vaccines
C. Slingluff Jr., Charlottesville, VA
9:20-9:45 Mechanism of synergistic effect of chemotherapy and
cancer vaccines
D. Gabrilovich, Tampa, FL
9:45-10:15 Coffee break
10:15-12.45 Session 2: Will there be a role for vaccines in anti-cancer therapy?
Co-Chairs: L.A. Emens, Baltimore, MD – J. Weber, Tampa,
FL
10:15-10:40 Multiple peptide vaccines in early melanoma and prostate
carcinoma
L. Rivoltini, Milan, Italy
10:40-11:05 Exploiting autophagy: cross-priming of tumor-specific T cells against short-lived proteins
W. J. Urba, Portland, OR
11:30-11:55 Can chemotherapy be successfully combined with cancer
vaccines?
L.A. Emens, Baltimore, MD
11:55-12:20 Drawbacks in cancer vaccines: Overcoming tolerance by exploiting immune regulatory molecules
J. Weber, Tampa, FL
12:20-12:45 Roundtable discussion: Lessons learned from developing anti-cancer vaccines
L.A. Emens, S. Endres, B.A. Fox, S. Khlief, M. Lotze, L. Rivoltini, C. Slingluff Jr., W.J. Urba, J. Weber
12:45-2:15 Lunch
2:15-3:30 Session 3: Designing optimal combinations for
immunotherapy
Co-Chairs: J. Becker, Würzburg – D. Rüttinger, Munich
2:15-2:40 OX40 costimulation as a therapeutic strategy for cancer immunotherapy: Preclinical and clinical results
A. Weinberg, Portland, OR
2:40-3:05 Drawbacks in cancer vaccines: Overcoming tolerance by exploiting immune regulatory molecules
J. Weber, Tampa, FL
2:40-3:05 Use of novel markers and chemokines for immunotherapy
J. Mulé, Tampa, FL
3:05-3:30 RNA oligonucleotides for immunotherapy of cancer
S. Endres, Munich
3:30-4:00 Coffee break
4:00-5:15 Session 4: Optimizing adoptive cell therapy
Co-Chairs: R. Morgan, Bethesda, MD – D.J. Schendel,
Munich
4:00-4:25 Selecting high-affinity T cells for adoptive T cell therapy
D.J. Schendel, Munich
4:25-4:50 HER2-reactive T cells for adoptive transfer in breast
cancer
H. Bernhard, Darmstadt
4:50-5:15 Genetically modified T cells for adoptive transfer
R. Morgan, Bethesda, MD
7 PM Dinner
Saturday July 4, 2009
9:00-10:00 Poster presentations/Poster Awardee Selection
Co-Chairs: M. Lotze, R.K. Puri, C. Slingluff Jr,
W. Zimmermann
10:00-10:50 Session 5: Targeted and novel immunotherapeutic
approaches
Co-Chairs: Ch. Itin, Munich – W. Urba, Portland, OR
10:00-10:25 Blinatumomab, a T-cell engaging bispecific antibody for the treatment of NHL
Ch. Itin, Munich
10:25-10:50 Catumaxomab (Removab): The road from preclinical development to approval
D. Seimetz, Munich
10:50-11:20 Coffee break
11:20-12:10 Session 5: continued
11:20-11:45 Targeting IL-13Ra2 for cancer therapy
R.K. Puri, Bethesda, MD
11:45-12:10 Melanoma stem cells: targets for immunotherapy?
J. Becker, Würzburg
12:10-1:45 Lunch
1:45-3:25 Session 6: Improving immunotherapeutic approaches
Co-Chairs: L. Zitvogel, Villejuif, France – S. Khleif, Bethesda, MD
1:45-2:10 The value of adding T help to clinical vaccine approaches
S. Khleif, Bethesda, MD
2:10-2:35 MAGE-A3 cancer immunotherapeutics in metastatic
melanoma
J.F. Baurain, Brussels, Belgium
2:35-3:00 Molecular pathways involved in the immunogenicity of chemotherapy in cancer
L. Zitvogel, Villejuif, France
3:00-3:25 Combining anti-tumor mAB and inibs: where are we and where are we heading for
R. Huber, Munich
3:25-4:00 Coffee break
4:00-5:00 Round table discussion: Overcoming obstacles to approval of combination biologics
Moderators: J. Weber, Tampa, FL - B.A. Fox, Portland OR
Regulatory issues for combination therapies (the US perspective)
R.K. Puri, Bethesda, MD
Regulatory issues for combination therapies (the EU perspective)
T. Hinz, Langen
5:00-5:15 Poster prize and closing remarks
J. Weber, Tampa, FL - B.A. Fox, Portland OR
The “Asklepios Poster Prize 2009 for innovative cancer therapy“ will be awarded to the winner by Prof. R.A. Hatz